Stirling, Scotland, 6 November 2024 – Prymexa is excited to announce a multi-million-pound partnership with iGii to develop an innovative toolkit designed to detect signs of perimenopause – the transitional phase before menopause that can begin as early as the mid-30s.
With 60% of women under 40 feeling uninformed about perimenopause and menopause, many face a range of symptoms and increased risks of depression, osteoporosis, and cardiovascular disease without adequate guidance. This lack of awareness and monitoring often leads to misdiagnosis and missed opportunities for early intervention. By identifying the perimenopause stage early, individuals can receive personalized advice, treatment, and support from healthcare professionals, gaining confidence through a better understanding of their symptoms.
The toolkit will explore various monitoring options, including wearable devices and sensors, to enable simple and affordable at-home monitoring that can be closely tracked by medical professionals.
Integral to this technology is iGii’s sustainable carbon nanomaterial, Gii, which offers a low-cost, eco-friendly, and highly sensitive alternative to traditional carbon and metal-based sensors, making it particularly effective for accurately assessing menopause symptoms.
Sara Pardoe, Chief Executive Officer, Prymexa, stated: “Menopause receives a fraction of the investment compared to other medical fields, yet half the population will experience it, and the demand for effective management solutions is growing exponentially. Our research aims to bring individuals closer to a simple, clear understanding of their menopause journey and how to best manage it.”
Jean-Christophe Granier, CEO, iGii, commented: “Gii has the potential to significantly improve point-of-care human diagnostics and make accurate, quick medical results the norm. Its properties provide a more affordable, sustainable, scalable, and sensitive sensing platform for high-quality results in labs and at home. This project with Prymexa highlights the real value and potential of Gii, and we look forward to working with them to positively impact the lives of those going through the perimenopause period.”
David Atkinson, Founder of Prymexa, shared his excitement about the groundbreaking collaboration with iGii: “We are thrilled about this partnership, which promises to transform lives through our extensive research and development efforts. By joining forces with iGii, we can enhance the precision and sensitivity of our toolkit, accelerating our product development and ultimately making a significant difference in people’s lives.”
Romy Williams and Sophie Stubbs, Directors at Prymexa, added: “Prymexa is continuously advancing and solidifying its position in the health monitoring industry. Our partnership with iGii further underscores our commitment to easing the perimenopausal and menopausal journey for individuals. By collaborating, we are enhancing our ability to offer comprehensive, supportive solutions tailored to the unique needs of those experiencing these significant life transitions. We are both thrilled about the incredible benefits our solutions will bring in the coming years.”
